References

rsp

Научно-практическая ревматология

Rheumatology Science and Practice

1995-44841995-4492

IMA-PRESS, LLC

10.47360/1995-4484-2021-643-663

rsp-3096

Research Article

ПЕРЕДОВАЯ

LEADING ARTICLE

Болезнь Стилла взрослых: новые горизонты

Adult Still's disease: New horizons

https://orcid.org/0000-0002-1598-8360

Насонов

Е. Л.

Nasonov

E. L.

Насонов Евгений Львович.

115522, Москва, Каширское шоссе, 34а; 119991, Москва, ул. Трубецкая, 8, стр. 2.

Evgeny L. Nasonov.

115522, Moscow, Kashirskoye Highway, 34A; 119991, Moscow, Trubetskaya str., 8, building 2.

nasonov@irramn.ru

https://orcid.org/0000-0002-9872-5282

Файст

Е.

Feist

39245, Гоммерн, Софи-в.-Беттихер-Штрассе, 1.

Eugen Feist.

39245, Gommern, Sophie-v.-Boetticher-Straße, 1.

Научно-исследовательский институт ревматологии им. В.А. Насоновой; Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian Federation

Отделение ревматологии Клиники Гелиос Фогельсанг-Гоммерн, партнер по сотрудничеству Магдебургского университета имени Отто фон ГерикеГерманияDepartment of Rheumatology, Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto-von-Guericke University MagdeburgGermany

2021

26122021

596645665

2021

Насонов Е.Л., Файст Е.

Nasonov E.L., Feist E.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://rsp.mediar-press.net/rsp/article/view/3096

Болезни Стилла у детей (системный ювенильный идиопатический артрит (ЮИА)) и у взрослых (болезнь Стилла взрослых (БСВ)) рассматриваются как системные аутовоспалительные заболевания неизвестной этиологии, в основе которых лежат сходные иммунопатогенетические механизмы, связанные с генетически детерминированными нарушениями механизмов врожденного иммунитета. БСВ впервые была описана 50 лет назад английским ревматологом Эриком Байуотерсом (Eric George Lapthorne Bywaters). Молекулярную основу иммунопатогенеза БСВ составляет активация врожденного иммунитета, связанная с NLRP3 инфламмасома-зависимыми механизмами воспаления, характеризуется гиперпродукцией «прово-спалительных» цитокинов — интерлейкина (ИЛ) 1 и ИЛ-18, — индуцирующих синтез других провоспалительных медиаторов воспаления. Представлен обзор новых данных, касающихся механизмов иммунопатологии, клинического полиморфизма, лабораторных биомаркеров и возможностей фармакотерапии БСВ.

Особое внимание уделено перспективам применения моноклональных антител к ИЛ-1β — канакинумаба. Рассматриваются проблемы, связанные с общностью клинико-лабораторных нарушений, патогенетических механизмов и фармакотерапии БСВ и коронавирусной болезни 2019 (COVID-19).

Still's disease in children (systemic juvenile idiopathic arthritis - JIA) and adult Still's disease (ASD) are considered as systemic autoinflammatory diseases of unknown etiology, which are based on similar immunopathogenetic mechanisms associated with genetically determined disorders of the mechanisms of innate immunity. ASD was first described 50 years ago by the English rheumatologist Eric George Lapthorne Bywaters. The molecular basis of ASD immunopathogenesis is the activation of innate immunity associated with NLRP3 inflammasome-dependent mechanisms of inflammation, characterized by the overproduction of “pro-inflammatory” cytokines - interleukin (IL) 1 and IL-18, inducing the synthesis of other proinflammatory inflammatory mediators. A review of new data concerning the mechanisms of immunopathology, clinical polymorphism, laboratory biomarkers and the possibilities of ASD pharmacotherapy is presented.

Particular attention is paid to the prospects for the use of monoclonal antibodies to IL-1β - canakinumab. The problems associated with the generality of clinical and laboratory disorders, pathogenetic mechanisms and pharmacotherapy of ASD and coronavirus disease 2019 (COVID-19) are considered.

болезнь Стилла взрослыхинтерлейкин 1COVID-19канакинумабгенно-инженерные биологические препараты

adult Still's diseaseinterleukin 1COVID-19canakinumabbiologics

References1

McGonagle D, McDermott MF. a proposed classification of the immunological diseases. PLoS Med. 2006;3:e297. doi: 10.1371/journal.pmed.0030297

Szekanecz Z, McInnes IB, Schett G, Szamosi S, Benkd S, Szucs G. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-595. doi: 10.1038/s41584-021-00652-9

Doria A, Zen M, Bettio S, Gatto M, Bassi N, Nalotto L, et al. Autoinflammation and autoimmunity: Bridging the divide. Autoimmun Rev. 2012;12(1):22-30. doi: 10.1016/j.autrev.2012.07.018

Насонов ЕЛ, Александрова ЕН, Новиков АА. Аутоиммунные ревматические заболевания - проблемы иммунопатологии и персонифицированной терапии. Вестник РАМН. 2015;70(2):169-182. doi: 10.15690/vramn.v70i2.1310

Nasonov EL, Alexandrova EN, Novikov AA. Autoimmune rheumatic diseases - Problems of immunopathology and personalized treatment. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk = Annals of the Russian Academy of Medical Sciences. 2015;70(2):169-182 (In Russ.). doi: 10.15690/vramn.v70i2.1310

Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016;12(1):14-24. doi: 10.1038/nrrheum.2016.166

Dinarello CA. the IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612-32. doi: 10.1038/s41584-019-0277-8

Насонов ЕЛ. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2018;56:19-27. doi: 10.14412/1995-4484-2018-19-27

Nasonov EL. the role of interleukin 1 in the development of human diseases. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56:19-27 (In Russ.). doi: 10.14412/1995-4484-2018-19-27

Mitrovic S, Fautrel B. Clinical phenotypes of adult-onset Still's disease: New insights from pathophysiology and literature findings. J Clin Med. 2021;10(12):2633. doi: 10.3390/jcm10122633

Ter Haar NM, Jansen MHA, Frenkel JF, Vastert SJ. How autoinflammation may turn into autoimmune inflammation: Insights from monogenetic and complex IL-1 mediated auto-inflammatory diseases. Clin Immunol. 2020;219:108538. doi: 10.1016/j.clim.2020.108538

Kessel C, Hedrich CM, Foell D. Innately adaptive or truly autoimmune: Is there something unique about systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2020;72(2):210-219. doi: 10.1002/art.41107

Still GF. on a form of chronic joint disease in children. Med Chir Trans. 1897;80:47-60.

Bywaters EG. Still's disease in the adult. Ann Rheum Dis. 1971;30(2):121-133. doi: 10.1136/ard.30.2.121

Betrains A, Staels F, Schrijvers R, Meyts I, Humblet-Baron S, De Langhe E, et al. Systemic autoinflammatory disease in adults. Autoimmun Rev. 2021;20(4):102774. doi: 10.1016/j.autrev.2021.102774

Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, et al. Biological classification of childhood arthritis: Roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021;17(5):257-269. doi: 10.1038/s41584-021-00590-6

Nirmala N, Brachat A, Feist E, Blank N, Specker C, Witt M, et al. Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015;13:50. doi: 10.1186/s12969-015-0047-3

Inoue N, Shimizu M, Tsunoda S, Kawano M, Matsumura M, Yachie A. Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis. Clin Immunol. 2016;169:8-13. doi: 10.1016/j.clim.2016.05.010

Segu-Verg6s C, Coma M, Kessel C, Smeets S, Foell D, Aldea A. Application of systems biology-based in silico tools to optimize treatment strategy identification in Still's disease. Arthritis Res Ther. 2021;23(1):126. doi: 10.1186/s13075-021-02507-w

Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still's disease. Nat Rev Rheumatol. 2018;14(10):603-618. doi: 10.1038/s41584-018-0081-x

Brown D, Trowsdale J, Allen R. the LILR family: Modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens. 2004;64(3):215-225. doi: 10.1111/j.0001-2815.2004.00290.x

Wang M, Liu M, Jia J, Shi H, Teng J, Liu H, et al. Association of the leukocyte immunoglobulin-like receptor A3 gene with neutrophil activation and disease susceptibility in adult-onset Still's disease. Arthritis Rheumatol. 2021;73(6):1033-1043. doi: 10.1002/art.41635

Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity. 2019;50(4):778-795. doi: 10.1016/j.immuni.2019.03.012

Jung JY, Kim JW, Suh CH, Kim HA. Roles of interactions between Toll-like receptors and their endogenous ligands in the pathogenesis of systemic juvenile idiopathic arthritis and adult-onset Still's disease. Front Immunol. 2020;11:583513. doi: 10.3389/fimmu.2020.583513

Rosario C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. the hyperferritinemic syndrome: Macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185. doi: 10.1186/1741-7015-11-185

Colafrancesco S, Alessandri C, Conti F, Priori R. COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? Autoimmun Rev. 2020;19(7):102573. doi: 10.1016/j.autrev.2020.102573

Ruscitti P, Berardicurti O, Di Benedetto P, Cipriani P, Iagnocco A, Shoenfeld Y, et al. Severe COVID-19, another piece in the puzzle of the hyperferritinemic syndrome. An immunomodulatory perspective to alleviate the storm. Front Immunol. 2020;11:1130. doi: 10.3389/fimmu.2020.01130

McGonagle D, Ramanan AV, Bridgewood C. Immune cartography of macrophage activation syndrome in the COVID-19 era. Nat Rev Rheumatol. 2021;17(3):145-157. doi: 10.1038/s41584-020-00571-1

Hu Q, Shi H, Zeng T, Liu H, Su Y, Cheng X, et al. Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still's disease. Arthritis Res Ther. 2019;21(1):9. doi: 10.1186/s13075-018-1800-z

Ahn MH, Han JH, Chwae YJ, Jung JY, Suh CH, Kwon JE, et al. Neutrophil extracellular traps may contribute to the pathogenesis in adult-onset Still's disease. J Rheumatol. 2019;46(12):1560-1569. doi: 10.3899/jrheum.181058

Jia J, Wang M, Ma Y, Teng J, Shi H, Liu H, et al. Circulating neutrophil extracellular traps signature for identifying organ involvement and response to glucocorticoid in adult-onset Still's disease: A machine learning study. Front Immunol. 2020;11:563335. doi: 10.3389/fimmu.2020.563335

Chen DY, Chen YM, Lan JL, Lin CC, Chen HH, Hsieh CW. Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease. Rheumatology (Oxford). 2010;49(12):2305-2312. doi: 10.1093/rheumatology/keq284

Jung JY, Choi B, Sayeed HM, Suh CH, Kim YW, Kim HA, et al. Characteristic patterns of HLA presentation and T cell differentiation in adult-onset Still's disease. Int J Immunopathol Pharmacol. 2018;32:2058738418791284. doi: 10.1177/2058738418791284

Shimojima Y, Kishida D, Ueno KI, Ushiyama S, Ichikawa T, Sekijima Y. Characteristics of circulating natural killer cells and their interferon-y production in active adult-onset Still disease. J Rheumatol. 2019;46(10):1268-1276. doi: 10.3899/jrheum.181192

Vandenhaute J, Wouters CH, Matthys P. Natural killer cells in systemic autoinflammatory diseases: A focus on systemic juvenile idiopathic arthritis and macrophage activation syndrome. Front Immunol. 2020;10:3089. doi: 10.3389/fimmu.2019.03089

Di Cola I, Ruscitti P, Giacomelli R, Cipriani P. the pathogenic role of interferons in the hyperinflammatory response on adult-onset Still's disease and macrophage activation syndrome: Paving the way towards new therapeutic targets. J Clin Med. 2021;10(6):1164. doi: 10.3390/jcm10061164

De Benedetti F, Prencipe G, Bracaglia C, Marasco E, Grom AA. Targeting interferon-y in hyperinflammation: opportunities and challenges. Nat Rev Rheumatol. 2021 Oct 5. doi: 10.1038/s41584-021-00694-z

Schett G. Resolution of inflammation in arthritis. Semin Immunopathol. 2019;41(6):675-679. doi: 10.1007/s00281-019-00768-x

Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. the associations of circulating CD4+CD25high regulatory T cells and TGF-в with disease activity and clinical course in patients with adult-onset Still's disease. Connect Tissue Res. 2010;51(5):370-377. doi: 10.3109/03008200903461462

Sun Y, Wang Z, Chi H, Hu Q, Ye J, Liu H, et al. Elevated serum levels of interleukin-10 in adult-onset Still's disease are associated with disease activity. Clin Rheumatol. 2019;38(11):3205-3210. doi: 10.1007/s10067-019-04642-x

Chi H, Liu D, Sun Y, Hu Q, Liu H, Cheng X, et al. Interleukin-37 is increased in adult-onset Still's disease and associated with disease activity. Arthritis Res Ther. 2018;20:54. doi: 10.1186/s13075-018-1555-6

Bamidis AD, Koehler P, di Cristanziano V, Rasche K, Demirel B, Bacher P, et al. First manifestation of adult-onset Still's disease after COVID-19. Lancet Rheumatol. 2021;3(5):e319-e321. doi: 10.1016/S2665-9913(21)00072-2

Leone F, Cerasuolo PG, Bosello SL, Verardi L, Fiori E, Cocciolillo F, et al. Adult-onset Still's disease following COVID-19 vaccination. Lancet Rheumatol. 2021;3(10):e678-e680. doi: 10.1016/S2665-9913(21)00218-6

Magliulo D, Narayan S, Ue F, Boulougoura A, Badlissi F. Adultonset Still's disease after mRNA COVID-19 vaccine. Lancet Rheumatol. 2021;3(10):e680-e682. doi: 10.1016/S2665-9913(21)00219-8

Jia J, Shi H, Liu M, Liu T, Gu J, Wan L, et al. Cytomegalovirus infection may trigger adult-onset Still's disease onset or relapses. Front Immunol. 2019;10:898. doi: 10.3389/fimmu.2019.00898

Chen DY, Chen YM, Chen HH, Hsieh CW, Gung NR, Hung WT, et al. Human parvovirus B19 nonstructural protein NS1 activates NLRP3 inflammasome signaling in adult-onset Still's disease. Mol Med Rep. 2018;17(2):3364-3371. doi: 10.3892/mmr.2017.8275

Tomaras S, Goetzke CC, Kallinich T, Feist E. Adult-onset Still's disease: Clinical aspects and therapeutic approach. J Clin Med. 2021;10(4):733. doi: 10.3390/jcm10040733

Efthimiou P, Kontzias A, Hur P, Rodha K, Ramakrishna GS, Nakasato P. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum. 2021;51(4):858-874. doi: 10.1016/j.semarthrit.2021.06.004

Муравьев ЮВ, Лебедева ВВ. Болезнь Стилла взрослых в настоящее время. Научно-практическая ревматология. 2017;55(3):272-276. doi: 10.14412/1995-4484-2017-272-276

Muravyev YuV, Lebedeva VV. Adult-onset Still's disease today. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(3):272-276 (In Russ.). doi: 10.14412/1995-4484-2017-272-276

Mitrovic S, Feist E, Fautrel B. Adult-onset Still's disease. In: Cimaz R (ed.). Periodic and non-periodic fevers, rare diseases of the immune system. Springer Nature Switzerland AG;2020:93-132. doi: 10.1007/978-3-030-19055-2_6

Bilgin E, Hayran M, Erden A, Armagan B, Sari A, KiliQ L, et al. Proposal for a simple algorithm to differentiate adult-onset Still's disease with other fever of unknown origin causes: A longitudinal prospective study. Clin Rheumatol. 2019;38(6):1699-1706. doi: 10.1007/s10067-019-04455-y

Maria AT, Le Quellec A, Jorgensen C, Touitou I, Rivifere S, Guilpain P. Adult onset Still's disease (AOSD) in the era of biologic therapies: Dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13(11):1149-1159. doi: 10.1016/j.autrev.2014.08.032

Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (Oxford). 2001;40(12):1398-1404. doi: 10.1093/rheumatology/40.12.1398

Ichida H, Kawaguchi Y, Sugiura T, Takagi K, Katsumata Y, Gono T, et al. Clinical manifestations of adult-onset Still's disease presenting with erosive arthritis: Association with low levels of ferritin and Interleukin-18. Arthritis Care Res (Hoboken). 2014;66(4):642-646. doi: 10.1002/acr.22194

Berardicurti O, Conforti A, Iacono D, Pantano I, Caso F, Emmi G, et al. Dissecting the clinical heterogeneity of adult-onset Still's disease, results from a multi-dimensional characterisation and stratification. Rheumatology (Oxford). 2021 Jan 6:keaa904. doi: 10.1093/rheumatology/keaa904

Mollaeian A, Chen J, Chan NN, Nizialek GA, Haas CJ. Adult onset Still's disease in the elderly: A case-based literature review. BMC Rheumatol. 2021;5(1):12. doi: 10.1186/s41927-021-00183-6

Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol. 2004;31:2189-2198.

Colina M, Zucchini W, Ciancio G, Orzincolo C, Trotta F, Govoni M. the evolution of adult-onset Still disease: An observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum. 2011;41(2):279-285. doi: 10.1016/j.semarthrit.2010.12.006

Mitrovic S, Fautrel B. Complications of adult-onset Still's disease and their management. Expert Rev Clin Immunol. 2018;14(5):351-365. doi: 10.1080/1744666X.2018.1465821

Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255-2273. doi: 10.1056/NEJMra2026131

Goda K, Kenzaka T, Hoshijima M, Yachie A, Akita H. Adultonset Still's disease with macrophage activation syndrome diagnosed and treated based on cytokine profiling: A case-based review. Rheumatol Int. 2020;40(1):145-152. doi: 10.1007/s00296-019-04446-x

Chen PK, Chen DY. An update on the pathogenic role of macrophages in adult-onset Still's disease and its implication in clinical manifestations and novel therapeutics. J Immunol Res. 2021;2021:8998358. doi: 10.1155/2021/8998358

Wang R, Li T, Ye S, Tan W, Zhao C, Li Y, et al. Macrophage activation syndrome associated with adult-onset Still's disease: a multicenter retrospective analysis. Clin Rheumatol. 2020;39(8):2379-2386. doi: 10.1007/s10067-020-04949-0

Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19(3):424-430.

Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, et al. Proposal for a new set of classification criteria for adult-onset Still disease. Medicine (Baltimore). 2002;81(3):194-200. doi: 10.1097/00005792-200205000-00003

Lebrun D, Mestrallet S, Dehoux M, Golmard JL, Granger B, Georgin-Lavialle S, et al. Validation of the Fautrel classification criteria for adult-onset Still's disease. Semin Arthritis Rheum. 2018;47(4):578-585. doi: 10.1016/j.semarthrit.2017.07.005

Pouchot J, Sampalis JS, Beaudet F, Carette S, D6cary F, Salusinsky-Sternbach M, et al. Adult Still's disease: Manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70(2):118-136.

Ruscitti P, Cipriani P, Masedu F, Iacono D, Ciccia F, Liakouli V, et al. Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14(1):194. doi: 10.1186/s12916-016-0738-8

Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis. J Rheumatol. 2010;37(11):2369-2376. doi: 10.3899/jrheum.100247

McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: Past, present and future. Nat Rev Immunol. 2021;21(10):680-686. doi: 10.1038/s41577-021-00603-1

Robinson WH, Lindstrom TM, Cheung RK, Sokolove J. Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol. 2013;9(5):267-276. doi: 10.1038/nrrheum.2013.14

Насонов ЕЛ. Ревматоидный артрит: Проблемы и значение персонифицированной медицины. Терапевтический архив. 2012;84(5):5-9.

Nasonov EL. Rheumatoid arthritis: Problems and significance of personalized medicine. Terapevticheskii arkhiv. 2012;84(5):5-9 (In Russ.).

Mitrovic S, Fautrel B. New markers for adult-onset Still's disease. Joint Bone Spine. 2018;85(3):285-293. doi: 10.1016/j.jbspin.2017.05.011

Di Benedetto P, Cipriani P, Iacono D, Pantano I, Caso F, Emmi G, et al. Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. PLoS One. 2020;15(7):e0235326. doi: 10.1371/journal.pone.0235326

Ha YJ, Kang EJ, Lee SW, Park YB, Lee SK, Song JS, et al. Serum leucine-rich a2-glycoprotein is a useful biomarker for monitoring disease activity in patients with adult-onset Still's disease. Scand J Rheumatol. 2015;44(5):399-403. doi: 10.3109/03009742.2015.1016103

Kirino Y, Kawaguchi Y, Tada Y, Tsukamoto H, Ota T, Iwamoto M, et al. Beneficial use of serum ferritin and heme oxyge-nase-1 as biomarkers in adult-onset Still's disease: A multicenter retrospective study. Mod Rheumatol. 2018;28(5):858-864. doi: 10.1080/14397595.2017

Guo Q, Zha X, Li C, Jia Y, Zhu L, Guo J, et al. Serum calprotect-in--a promising diagnostic marker for adult-onset Still's disease. Clin Rheumatol. 2016;35(1):73-79. doi: 10.1007/s10067-015-3108-6

Kim HA, An JM, Nam JY, Jeon JY, Suh CH. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still's disease. J Rheumatol. 2012;39(7):1399-1406. doi: 10.3899/jrheum.120079

Kim HA, Han JH, Kim WJ, Noh HJ, An JM, Yim H, et al. TLR4 endogenous ligand S100A8/A9 levels in adult-onset Still's disease and their association with disease activity and clinical manifestations. Int J Mol Sci. 2016;17(8):1342. doi: 10.3390/ijms17081342

Bae CB, Suh CH, An JM, Jung JY, Jeon JY, Nam JY, et al. Serum S100A12 may be a useful biomarker of disease activity in adult-onset Still's disease. J Rheumatol. 2014;41(12):2403-2408. doi: 10.3899/jrheum.140651

Scirfe CA, Cavagna L, Perotti C, Bruschi E, Caporali R, Montecucco C. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006;24(2):123-128.

Gowin E, Wysocki J. Limited diagnostic value of procalcitonin in early diagnosis of adult onset Still's disease. Reumatologia. 2016;54(4):207-211. doi: 10.5114/reum.2016.62476

Buhaescu I, Yood RA, Izzedine H. Serum procalcitonin in systemic autoimmune diseases - Where are we now? Semin Arthritis Rheum. 2010;40(2):176-183. doi: 10.1016/j.semarthrit.2009.10.004

Koga T, Sumiyoshi R, Furukawa K, Sato S, Migita K, Shimizu T, et al. Interleukin-18 and fibroblast growth factor 2 in combination is a useful diagnostic biomarker to distinguish adult-onset Still's disease from sepsis. Arthritis Res Ther. 2020;22(1):108. doi: 10.1186/s13075-020-02200-4

Zhang W, Yang T, Zhang H, Xu Y, Yang Q, Liu G, et al. Biomarker screening and validation for the differentiation of bloodstream infection from adult-onset Still's disease: A prospective cohort study. Cytokine. 2021;146:155642. doi: 10.1016/j.cyto.2021.155642

Kudela H, Drynda S, Lux A, Horneff G, Kekow J. Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still's disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity. BMC Rheumatol. 2019;3:4. doi: 10.1186/s41927-019-0053-z

Priori R, Colafrancesco S, Alessandri C, Minniti A, Perricone C, Iaiani G, et al. Interleukin 18: A biomarker for differential diagnosis between adult-onset Still's disease and sepsis. J Rheumatol. 2014;41(6):1118-1123. doi: 10.3899/jrheum.130575

Girard C, Rech J, Brown M, Allali D, Roux-Lombard P, Spertini F, et al. Elevated serum levels of free interleukin-18 in adult-onset Still's disease. Rheumatology (Oxford). 2016;55(12):2237-2247. doi: 10.1093/rheumatology/kew300

Nam SW, Kang S, Lee JH, Yoo DH. Different features of interleu-kin-37 and interleukin-18 as disease activity markers of adult-onset Still's disease. J Clin Med. 2021;10(5):910. doi: 10.3390/jcm10050910

Han JH, Suh CH, Jung JY, Ahn MH, Kwon JE, Yim H, et al. Serum levels of interleukin 33 and soluble ST2 are associated with the extent of disease activity and cutaneous manifestations in patients with active adult-onset Still's disease. J Rheumatol. 2017;44(6):740-747. doi: 10.3899/jrheum.170020

Ghannam K, Zernicke J, Kedor C, Listing J, Burmester GR, Foell D, et al. Distinct effects of interleukin-1e inhibition upon cytokine profile in patients with adult-onset Still's disease and active articular manifestation responding to canakinumab. J Clin Med. 2021;10(19):4400. doi: 10.3390/jcm10194400

Hoshino T, Ohta A, Yang D, Kawamoto M, Kikuchi M, Inoue Y, et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol. 1998;25(2):396-398.

Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005;52(6):1794-1803. doi: 10.1002/art.21061

Willeke P. Potential role of macrophage migration inhibitory factor in adult-onset Still's disease. Scand J Rheumatol. 2009;38(1):69-71. doi: 10.1080/03009740802179701

Zou YQ, Lu LJ, Li SJ, Zeng T, Wang XD, Bao CD, et al. the levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still's disease. Clin Biochem. 2008;41(7-8):519-524. doi: 10.1016/j.clinbiochem.2008.01.008

Han JH, Suh CH, Jung JY, Ahn MH, Han MH, Kwon JE, et al. Elevated circulating levels of the interferon-y-induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still's disease. Sci Rep. 2017;7:46652. doi: 10.1038/srep46652

Han JH, Suh CH, Jung JY, Nam JY, Kwon JE, Yim H, et al. Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still's disease. Arthritis Res Ther. 2015;17(1):260. doi: 10.1186/s13075-015-0773-4

Liu Y, Zhang S, Xia CS, Chen J, Fan C. Elevated granulocyte colony-stimulating factor levels in patients with active phase of adult-onset Still disease. J Rheumatol. 2021;48(5):664-668. doi: 10.3899/jrheum.200617

Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, et al. Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol. 2003;30(11):2422-2427.

Matsui K, Tsuchida T, Hiroishi K, Tominaga K, Hayashi N, Hada T, et al. High serum level of macrophage-colony stimulating factor (M-CSF) in adult-onset Still's disease. Rheumatology (Oxford). 1999;38(5):477-478. doi: 10.1093/rheumatology/38.5.477

100

Chen YM, Hung WT, Chang WC, Hsieh CW, Chung WH, et al. Genetic association and expression correlation between colonystimulating factor 1 gene encoding M-CSF and adult-onset Still's disease. J Immunol Res. 2020;2020:8640719. doi: 10.1155/2020/8640719

101

Colafrancesco S, Priori R, Alessandri C, Astorri E, Perricone C, Blank M, et al. sCD163 in AOSD: A biomarker for macrophage activation related to hyperferritinemia. Immunol Res. 2014;60(2-3):177-183. doi: 10.1007/s12026-014-8563-7

102

Chen DY, Chen YM, Lin CC, Hsieh CW, Wu YC, Hung WT, et al. the potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still's disease. BMC Musculoskelet Disord. 2015;16:111. doi: 10.1186/s12891-015-0569-3

103

Chen DY, Lan JL, Lin FJ, Hsieh TY. Association of intercellular adhesion molecule-1 with clinical manifestations and interleu-kin-18 in patients with active, untreated adult-onset Still's disease. Arthritis Rheum. 2005;53(3):320-327. doi: 10.1002/art.21164

104

Wang Z, Chi H, Sun Y, Teng J, Feng T, Liu H, et al. Serum sTREM-1 in adult-onset Still's disease: A novel biomarker of disease activity and a potential predictor of the chronic course. Rheumatology (Oxford). 2020;59(11):3293-3302. doi: 10.1093/rheumatology/keaa135

105

Jung JY, Suh CH, Sohn S, Nam JY, Kim HA. Elevated high-mobility group B1 levels in active adult-onset Still's disease associated with systemic score and skin rash. Clin Rheumatol. 2016;35(8):1937-1942. doi: 10.1007/s10067-016-3314-x

106

Tian R, Chen X, Yang C, Teng J, Qu H, Liu HL. Serum heparin-binding protein as a potential biomarker to distinguish adult-onset Still's disease from sepsis. Front Immunol. 2021;12:654811. doi: 10.3389/fimmu.2021.654811

107

Chen X, Hu QY, Wang M, Jia J, Teng J, Sun Y, et al. Serum VEGF-C as an evaluation marker of disease activity in adult-onset Still's disease. Rheumatol Int. 2021 Sep 9. doi: 10.1007/s00296-021-04978-1

108

Jia J, Yang L, Cao Z, Wang M, Ma Y, Ma X, et al. Neutrophil-derived lipocalin-2 in adult-onset Still's disease: A novel biomarker of disease activity and liver damage. Rheumatology (Oxford). 2021;60(1):304-315. doi: 10.1093/rheumatology/keaa368

109

Fujita Y, Yago T, Asano T, Matsumoto H, Matsuoka N, Temmoku J, et al. Clinical relevance for circulating cold-inducible RNA-binding protein (CIRP) in patients with adult-onset Still's disease. PLoS One. 2021;16(8):e0255493. doi: 10.1371/journal.pone.0255493

110

Fujita Y, Asano T, Matsumoto H, Matsuoka N, Temmoku J, Sato S, et al. Elevated serum levels of checkpoint molecules in patients with adult Still's disease. Arthritis Res Ther. 2020;22(1):174. doi: 10.1186/s13075-020-02263-3

111

Wakabayashi K, Inokuma S, Matsubara E, Onishi K, Asashima H, Nakachi S, et al. Serum e2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adult-onset Still's disease. Clin Rheumatol. 2013;32(7):999-1005. doi: 10.1007/s10067-013-2220-8

112

Liao TL, Chen YM, Hsieh CW, Chen HH, Lee HC, Hung WT, et al. Upregulation of circulating microRNA-134 in adult-onset Still's disease and its use as potential biomarker. Sci Rep. 2017;7(1):4214. doi: 10.1038/s41598-017-04086-w

113

Hu Q, Gong W, Gu J, Geng G, Li T, Tian R, et al. Plasma microRNA profiles as a potential biomarker in differentiating adult-onset Still's disease from sepsis. Front Immunol. 2019;9:3099. doi: 10.3389/fimmu.2018.03099

114

Zhang M, Xie M, Wang Y, Li J, Zhou J. Combination value of biomarkers in discriminating adult onset Still's disease and sepsis. Wien Klin Wochenschr. 2021;133(3-4):118-122. doi: 10.1007/s00508-020-01668-z

115

Liu Y, Xia C, Chen J, Fan C, He J. Elevated circulating pro-inflammatory low-density granulocytes in adult-onset Still's disease. Rheumatology (Oxford). 2021;60(1):297-303. doi: 10.1093/rheumatology/keaa324

116

Hsieh CW, Chen YM, Lin CC, Tang KT, Chen HH, Hung WT, et al. Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset Still disease. J Rheumatol. 2017;44(8):1142-1150. doi: 10.3899/jrheum.161354

117

Chen PK, Hsieh SL, Lan JL, Lin CC, Chang SH, Chen DY. Elevated expression of C-Type lectin domain family 5-mem-ber a (CLEC5A) and its relation to inflammatory parameters and disease course in adult-onset Still's disease. J Immunol Res. 2020;9473497. doi: 10.1155/2020/9473497

118

Shimizu T, Kikuchi-Taura A, Tsuji S, Matsushita M, Ohshima S, Saeki Y. Up-regulation of CD64 expression on monocytes in patients with active adult-onset Still disease: A possible biomarker of disease activity. J Clin Rheumatol. 2020;26(2):67-72. doi: 10.1097/RHU.0000000000000931

119

Sun Y, Wang F, Zhou Z, Teng J, Su Y, Chi H, et al. Urinary proteomics identifying novel biomarkers for the diagnosis of adult-onset Still's disease. Front Immunol. 2020;11:2112. doi: 10.3389/fimmu.2020.02112

120

Cavalli G, Farina N, Campochiaro C, Baldissera E, Dagna L. Current treatment options and safety considerations when treating adult-onset Still's disease. Expert Opin Drug Saf. 2020;19(12):1549-1558. doi: 10.1080/14740338.2020.1839411

121

Ma Y, Meng J, Jia J, Wang M, Teng J, Zhu D, et al. Current and emerging biological therapy in adult-onset Still's disease. Rheumatology (Oxford). 2021;60(9):3986-4000. doi: 10.1093/rheumatology/keab485

122

Colafrancesco S, Manara M, Bortoluzzi A, Serban T, Bianchi G, Cantarini L, et al.; AOSD Consensus Group. Management of adult-onset Still's disease with interleukin-1 inhibitors: Evidence- and consensus-based statements by a panel of Italian experts. Arthritis Res Ther. 2019;21(1):275. doi: 10.1186/s13075-019-2021-9

123

Mimura T, Kondo Y, Ohta A, Iwamoto M, Ota A, Okamoto N, et al. Evidence-based clinical practice guideline for adult Still's disease. Mod Rheumatol. 2018;28(5):736-757. doi: 10.1080/14397595.2018.1465633

124

Vastert SJ, Jamilloux Y, Quartier P, Ohlman S, Osterling Koskinen L, Kullenberg T, et al. Anakinra in children and adults with Still's disease. Rheumatology (Oxford). 2019;58(Suppl 6):vi9-vi22. doi: 10.1093/rheumatology/kez350

125

Giacomelli R, Sota J, Ruscitti P, Campochiaro C, Colafrancesco S, Dagna L, et al. the treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: A systematic review of literature. Clin Exp Rheumatol. 2021;39(1):187-195.

126

Tang S, Li S, Zheng S, Ding Y, Zhu D, Sun C, et al. Understanding of cytokines and targeted therapy in macrophage activation syndrome. Semin Arthritis Rheum. 2021;51(1):198-210. doi: 10.1016/j.semarthrit.2020.12.007

127

Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, et al. Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment: A randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77(12):1720-1729. doi: 10.1136/annrheumdis-2018-213920

128

Reihl Crnogaj M, Cubelic D, Babic A, Mayer M, Anic B. Treatment of refractory adult onset Still's disease with tocili-zumab - a single centre experience and literature review. Rheumatol Int. 2020;40(8):1317-1325. doi: 10.1007/s00296-020-04622-4

129

Kaneko Y. Interluekin-6 inhibitors for the treatment of adult-onset Still's disease. Modern Rheumatol. 2021;roab004. doi: 10.1093/mr/roab004

130

Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of refractory adult onset Still's disease with rituximab. Ann Rheum Dis. 2006;65(8):1117-1118. doi: 10.1136/ard.2005.047621

131

Lee WS, Yoo WH. Rituximab for refractory adult-onset Still's disease with thrombotic microangiopathy. Rheumatology (Oxford). 2014;53(9):1717-1718. doi: 10.1093/rheumatology/keu027

132

Padilla-Ibarra J, Sanchez-Ortiz A, Sandoval-Castro C, Ramos-Remus C. Rituximab treatment for pulmonary arterial hypertension in adult-onset Still's disease. Clin Exp Rheumatol. 2013;31(4):657-658.

133

Mohammed R. Anti-CD-20 therapy in refractory adult Still's disease. Open J Rheumatol Autoimmune Dis. 2012;2(2):3-5. doi: 10.4236/ojra.2012.22002

134

Ostrowski RA, Tehrani R, Kadanoff R. Refractory adult-onset Still disease successfully treated with abatacept. J Clin Rheumatol. 2011;17(6):315-317. doi: 10.1097/RHU.0b013e31822c53ad

135

Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still's disease. Clin Exp Rheumatol. 2010;28(2):265-267.

136

Hu Q, Wang M, Jia J, Teng J, Chi H, Liu T, et al. Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China. Ann Rheum Dis. 2020;79(6):842-844. doi: 10.1136/annrheumdis-2019-216699

137

Honda M, Moriyama M, Kondo M, Kumakura S, Murakawa Y. Tofacitinib-induced remission in refractory adult-onset Still's disease complicated by macrophage activation syndrome. Scand J Rheumatol. 2020;49(4):336-338. doi: 10.1080/03009742.2020.1729405

138

Kacar M, Fitton J, Gough AK, Buch MH, McGonagle DG, Savic S. Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoin-flammatory disease. RMD Open. 2020;6(2):e001246. doi: 10.1136/rmdopen-2020-001246

139

Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kotter I, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Ann Rheum Dis. 2018;77(6):840-847. doi: 10.1136/annrheumdis-2017-212608

140

Kiltz U, Kiefer D, Braun J, Schiffrin EJ, Girard-Guyonvarc'h C, Gabay C. Prolonged treatment with Tadekinig alfa in adult-onset Still's disease. Ann Rheum Dis. 2020;79(1):e10. doi: 10.1136/annrheumdis-2018-214496

141

Gabr JB, Liu E, Mian S, Pillittere J, Bonilla E, Banki K, et al. Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still's disease: Case report and review of the literature. Ann Transl Med. 2020;8(14):887. doi: 10.21037/atm-20-3127

142

De Benedetti F, Brogan P, Grom A, Quartier P, Schneider R, Ant6n J, et al. Interferon-gamma (IFN-y) neutralization with ema-palumab and time to response in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (s-JIA) who failed high-dose glucocorticoids [abstract]. Arthritis Rheumatol. 2019;71(Suppl 10). URL: https://acrabstracts.org/abstract/interferon-gamma-ifn-%ce%b3-neutralization-with-emapal-umab-and-time-to-response-in-patients-with-macrophage-activation-syndrome-mas-complicating-systemic-juvenile-idio-pathic-arthritis-s-jia-who [Accessed: DD Month YEAR].

143

Gram H. Preclinical characterization and clinical development of ILARIS(®) (canakinumab) for the treatment of autoinflammatory diseases. Curr Opin Chem. 2016;32:1-9. doi: 10.1016/j.cbpa.2015.12.003

144

Gram H. the long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer. Pharmacol Res. 2020;154:104139. doi: 10.1016/j.phrs.2019.01.023

145

Sun H, Van LM, Floch D, Jiang X, Klein UR, Abrams K, et al. Pharmacokinetics and pharmacodynamics of canakinumab in patients with systemic juvenile idiopathic arthritis. J Clin Pharmacol. 2016;56(12):1516-1527. doi: 10.1002/jcph.754

146

Cota-Arce JM, Cota J, De Le6n-Nava MA, Herndndez-CAceres A, Moncayo-Salazar LI, Valle-Alvarado F, et al. Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: A systematic review. Semin Arthritis Rheum. 2021 Aug 27:S0049-0172(21)00161-X. doi: 10.1016/j.semarthrit.2021.08.007

147

Sfriso P, Bindoli S, Doria A, Feist E, Galozzi P. Canakinumab for the treatment of adult-onset Still's disease. Expert Rev Clin Immunol. 2020;16(2):129-138. doi: 10.1080/1744666X.2019.1707664

148

Насонов ЕЛ. Применение канакинумаба при болезни Стилла взрослых. Научно-практическая ревматология. 2018;56:35-40. doi: 10.14412/1995-4484-2018-35-40

Nasonov EL. Therapy with canakinumab for adult-onset Still's disease. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56:35-40 (In Russ.). doi: 10.14412/1995-4484-2018-35-40

149

Kontzias A, Efthimiou P. the use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still's disease. Semin Arthritis Rheum. 2012;42(2):201-205. doi: 10.1016/j.semarthrit.2012.03.004

150

Banse C, Vittecoq O, Benhamou Y, Gauthier-Prieur M, Lequerrt T, Levesque H. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. Joint Bone Spine. 2013;80(6):653-655. doi: 10.1016/j.jbspin.2013.04.011

151

Eriksson P, Jacobs C, Soderkvist P. a patient with a phenotype of adult-onset Still disease, but a genotype typical of cryopyrin-associated periodic fever syndrome. J Rheumatol. 2013;40(9):1632-1633. doi: 10.3899/jrheum.130325

152

Barsotti S, Neri R, Iacopetti V, d'Ascanio A, Talarico R, Tripoli A, et al. Successful treatment of refractory adult-onset Still disease with canakinumab: A case report. J Clin Rheumatol. 2014;20(2):121. doi: 10.1097/RHU.0000000000000082

153

Lo Gullo A, Caruso A, Pipitone N, Macchioni P, Pazzola G, Salvarani C. Canakinumab in a case of adult onset Still's disease: Efficacy only on systemic manifestations. Joint Bone Spine. 2014;81(4):376-377. doi: 10.1016/j.jbspin.2013.12.011

154

Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, et al.; MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study Group on behalf of CRI (Club Rhumatisme et Inflammation). Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: A nationwide survey. Orphanet J Rare Dis. 2015;10:19. doi: 10.1186/s13023-015-0228-7

155

Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E, et al. Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still's disease: A multicentre retrospective observational study. Front Pharmacol. 2017;8:369. doi: 10.3389/fphar.2017.00369

156

Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, et al. Efficacy and safety of canakinumab in patients with Still's disease: Exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018;36(4):668-675.

157

Schwartz C, Taylor A, Zaidi Z. Expand the differential... Think beyond rheumatoid arthritis. BMJ Case Rep. 2018;2018:bcr2018225618. doi: 10.1136/bcr-2018-225618

158

Breillat P, Tourte M, Romero P, Hayem G, Padovano I, Costantino F, et al. Interleukin-1 inhibitors and dacryoadenitis in adult-onset Still disease. Ann Intern Med. 2018;168(6):455-456. doi: 10.7326/L17-0401

159

Cavalli G, Tomelleri A, De Luca G, Campochiaro C, Dinarello CA, Baldissera E, et al. Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis Res Ther. 2019;21(1):54. doi: 10.1186/s13075-019-1843-9

160

Chamseddin B, Marks E, Dominguez A, Wysocki C, Vandergriff T. Refractory macrophage activation syndrome in the setting of adult-onset Still disease with hemophagocytic lymphohistiocytosis detected on skin biopsy treated with canak-inumab and tacrolimus. J Cutan Pathol. 2019;46(7):528-531. doi: 10.1111/cup.13466

161

Khairoun M, Meynen F, Vercoutere W, Leavis HL. Case series of three adult patients with exceptional clinical presentations of haemophagocytic lymphohistiocytosis. Neth J Med. 2020;78(3):136-141.

162

Kedor C, Listing J, Zernicke J, WeiB A, Behrens F, Blank N, et al. Canakinumab for treatment of adult-onset Still's disease to achieve reduction of arthritic manifestation (CONSIDER): Phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis. 2020;79(8):1090-1097. doi: 10.1136/annrheumdis-2020-217155

163

Vitale A, Berlengiero V, Sota J, Ciarcia L, Ricco N, Barneschi S, et al. Real-life data on the efficacy of canakinumab in patients with adult-onset Still's disease. Mediators Inflamm. 2020;8054961. doi: 10.1155/2020/8054961

164

Laskari K, Tektonidou MG, Katsiari C, Athanassiou P, Dimopoulou D, Gerodimos C, et al. Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients. Semin Arthritis Rheum. 2021;51(1):137-143. doi: 10.1016/j.semarthrit.2020.10.011

165

Campochiaro C, Tomelleri A, Giacomo D, Farina N, Baldissera E, Cavalli G, et al. Efficacy of canakinumab treatment in adult-onset Still's disease [abstract]. Arthritis Rheumatol. 2019;71(Suppl 10). URL: https://acrabstracts.org/abstract/effica-cy-of-canakinumab-treatment-in-adult-onset-stills-disease [Accessed: 15th October 2021].

166

Nolmellen A, Campochiaro C, de Luca G, Farina N, Baldissera E, Cavalli G, et al. FRI0506 Efficacy and safety of canakinumab in adult-onset Still's disease: A single-center real-life experience. Ann Rheum Dis. 2020. doi: 10.1136/annrheumdis-2020-eular.2352

167

Vercruysse F, Barnetche T, Lazaro E, Shipley E, Lifermann F, Balageas A, et al. Still's disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther. 2019;21(1):53. doi: 10.1186/s13075-019-1838-6

168

Hinze T, Kessel C, Hinze CH, Seibert J, Gram H, Foell D. A dys-regulated interleukin-18/interferon-Y/CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2021 Feb 10:keab113. doi: 10.1093/rheumatology/keab113

169

Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19): Размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-132. doi: 10.14412/1995-4484-2020-123-132

Nasonov EL. Coronavirus disease 2019 (COVID-19): A rheumatologist's thoughts. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(2):123-132 (In Russ.). doi: 10.14412/1995-4484-2020-123-132

170

Zhou T, Su TT, Mudianto T, Wang J. Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. J Exp Med. 2020;217(10):e20200674. doi: 10.1084/jem.20200674

171

Christie MJ, Irving AT, Forster SC, Marsland BJ, Hansbro PM, Hertzog PJ, et al. of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. Sci Immunol. 2021;6(63):eabd0205. doi: 10.1126/sciimmunol.abd0205

172

Vora SM, Lieberman J, Wu H. Inflammasome activation at the crux of severe COVID-19. Nat Rev Immunol. 2021 Aug 9:1-10. doi: 10.1038/s41577-021-00588-x

173

Rodrigues TS, de S£ KSG, Ishimoto AY, Becerra A, Oliveira S, Almeida L, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2021;218(3):e20201707. doi: 10.1084/jem.20201707

174

Pan P, Shen M, Yu Z, Ge W, Chen K, Tian M, et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nat Commun. 2021;12(1):4664. doi: 10.1038/s41467-021-25015-6

175

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5

176

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3

177

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-2629. doi: 10.1172/JCI137244

178

Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, de Jesus AAA, et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2021;6(1):144455. doi: 10.1172/jci.insight.144455

179

Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9

180

Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463-469. doi: 10.1038/s41586-020-2588-y

181

Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5

182

Kessel C, Vollenberg R, Masjosthusmann K, Hinze C, Wittkowski H, Debaugnies F, et al. Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes using disease-related blood biomarkers. Arthritis Rheumatol. 202;73(10):1791-1799. doi: 10.1002/art.41763

183

Meng J, Ma Y, Jia J, Wang M, Teng J, Shi H, et al. Cytokine storm in coronavirus disease 2019 and adult-onset Still's disease: Similarities and differences. Front Immunol. 2021;11:603389. doi: 10.3389/fimmu.2020.603389

184

Kondo Y, Kaneko Y, Takei H, Tamai H, Kabata H, Suhara T, et al.; Keio Donner Project. COVID-19 shares clinical features with anti-melanoma differentiation-associated protein 5 positive dermatomyositis and adult Still's disease. Clin Exp Rheumatol. 2021;39(3):631-638.

185

Udomsinprasert W, Jittikoon J, Sangroongruangsri S, Chaikledkaew U. Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis. J Clin Immunol. 2021;41(1):11-22. doi: 10.1007/s10875-020-00899-z.

186

Sati§ H, Ozger HS, Aysert Yildiz P, Hizel K, Gulbahar O, Erba§ G, et al. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19. Cytokine. 2021;137:155302. doi: 10.1016/j.cyto.2020.155302

187

Chen Y, Wang J, Liu C, Su L, Zhang D, Fan J, et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med. 2020;26(1):97. doi: 10.1186/s10020-020-00230-x

188

Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, Liew F, Russell CD, et al.; ISARIC4C investigators. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci Immunol. 2021;6(57):eabg9873. doi: 10.1126/sciimmunol.abg9873

189

Caniglia JL, Asuthkar S, Tsung AJ, Guda MR, Velpula KK. Immunopathology of galectin-3: An increasingly promising target in COVID-19. F1000Res. 2020;9:1078. doi: 10.12688/f1000research.25979.2

190

Bozorgmehr N, Mashhouri S, Perez Rosero E, Xu L, Shahbaz S, Sligl W, et al. Galectin-9, a player in cytokine release syndrome and a surrogate diagnostic biomarker in SARS-CoV-2 infection. mBio. 2021;12(3):e00384-21. doi: 10.1128/mBio.00384-21

191

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0

192

Mangalmurti N, Hunter CA. Cytokine storms: Understanding COVID-19. Immunity. 2020;53(1):19-25. doi: 10.1016/j.immuni.2020.06.017

193

Veras FP, Pontelli MC, Silva CM, Toller-Kawahisa JE, de Lima M, Nascimento DC, et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med. 2020;217(12):e20201129. doi: 10.1084/jem.20201129

194

Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11):e138999. doi: 10.1172/jci.insight.138999

195

Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет. Научно-практическая ревматология. 2021;59(1):5-30. doi: 10.47360/1995-4484-2021-5-30

Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(1):5-30 (In Russ.). doi: 10.47360/1995-4484-2021-5-30

196

Wagner C, Griesel M, Mikolajewska A, Mueller A, Nothacker M, Kley K, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;8(8):CD014963. doi: 10.1002/14651858.CD014963

197

Geng J, Wang F, Huang Z, Chen X, Wang Y. Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19. Cytokine. 2021;143:155544. doi: 10.1016/j.cyto.2021.155544

198

Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P, et al.; International Collaborative Group for Anakinra in COVID-19. Effect of anakinra on mortality in patients with COVID-19: A systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021;3(10):e690-e697. doi: 10.1016/S2665-9913(21)00216-2

199

Generali D, Bosio G, Malberti F, Cuzzoli A, Testa S, Romanini L, et al. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. Int J Infect Dis. 2021;104:433-440. doi: 10.1016/j.ijid.2020.12.073

200

Landi L, Ravaglia C, Russo E, Cataleta P, Fusari M, Boschi A, et al. Blockage of interleukin-ie with canakinumab in patients with Covid-19. Sci Rep. 2020;10(1):21775. doi: 10.1038/s41598-020-78492-y

201

Katia F, Myriam DP, Ucciferri C, Auricchio A, Di Nicola M, Marchioni M, et al. Efficacy of canakinumab in mild or severe COVID-19 pneumonia. Immun Inflamm Dis. 2021;9(2):399-405. doi: 10.1002/iid3.400

202

CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): A randomised controlled trial. Lancet Respir Med. 2021:S2213-2600(20)30556-7. doi: 10.1016/S2213-2600(20)30556-7

203

Caricchio R, Abbate A, Gordeev I, Meng J, Hsue PY, Neogi T, et al.; CAN-COVID Investigators. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: A randomized clinical trial. JAMA. 2021;326(3):230-239. doi: 10.1001/jama.2021.9508

204

Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. doi: 10.1016/j.biopha.2020.110698

205

Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PLoS Med. 2020;17(12):e1003501. doi: 10.1371/journal.pmed.1003501

206

REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491-1502. doi: 10.1056/NEJMoa2100433

207

Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, et al.; TOCIVID-19 investigators, Italy. Tocilizumab for patients with COVID-19 pneumonia. the single-arm TOCIVID-19 prospective trial. J Transl Med. 2020;18(1):405. doi: 10.1186/s12967-020-02573-9

208

McGonagle D, Watad A, Savic S. Mechanistic immunological based classification of rheumatoid arthritis. Autoimmun Rev. 2018;17(11):1115-1123. doi: 10.1016/j.autrev.2018.06.001

209

Savic S, Mistry A, Wilson AG, Barcenas-Morales G, Doffinger R, Emery P, et al. Autoimmune-autoinflammatory rheumatoid arthritis overlaps: A rare but potentially important subgroup of diseases. RMD Open. 2017;3(2):e000550. doi: 10.1136/rmdopen-2017-000550

210

Cuervo A, Sanmartl R, Ramirez J, Castellanos-Moreira R, Inciarte-Mundo J, Ardstegui JI, et al. Palindromic rheumatism: Evidence of four subtypes of palindromic-like arthritis based in either MEFV or rheumatoid factor/ACPA status. Joint Bone Spine. 2021;88(6):105235. doi: 10.1016/j.jbspin.2021.105235

211

Cahete JD, Arostegui JI, Queird R, Gratacds J, HernAndez MV, Larrosa M, et al. An unexpectedly high frequency of MEFV mutations in patients with anti-citrullinated protein antibody-negative palindromic rheumatism. Arthritis Rheum. 2007;56(8):2784-2788. doi: 10.1002/art.22755

212

Mitrovic S, Hassold N, Kamissoko A, Rosine N, Mathian A, Mercy G, et al. Adult-onset Still's disease or systemic-onset juvenile idiopathic arthritis and spondyloarthritis: Overlapping syndrome or phenotype shift? Rheumatology (Oxford). 2021 Sep 24:keab726. doi: 10.1093/rheumatology/keab726

213

Rajabally MN, Watermeyer GA, Levin DA. a case of Crohn's disease complicated by adult onset Still's disease. J Crohns Colitis. 2010;4(4):475-478. doi: 10.1016/j.crohns.2010.02.010

214

Katsanos KH, Siozopoulou V, Sigounas D, Tsianos VE, Christodoulou D, et al. Adult-onset Still's disease preceding Crohn's disease. J Crohns Colitis. 2013;7(3):e93-e98. doi: 10.1016/j.crohns.2012.05.019

215

Kono M, Oshitani N, Sawa Y, Watanabe K, Kamata N, Oiso R, et al. Crohn's disease complicated by adult-onset Still's disease. J Gastroenterol. 2003;38(9):891-895. doi: 10.1007/s00535-002-1167-3

216

Semiz H, Kobak S. Coexistence of sarcoidosis and adult onset Still disease. Reumatol Clin (Engl Ed). 2019;15(5):e18-e20. doi: 10.1016/j.reuma.2017.04.004

217

Ganhao S, Ferreira RM, Guerra M, Furtado A, Agueda A, Mariz E, et al. Adult-onset Still's disease in a patient with a previous diagnosis of acute sarcoidosis: A rare association. J Clin Rheumatol. 2021;27(7):e271. doi: 10.1097/RHU.0000000000001404

218

Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020;383(27):2628-2638. doi: 10.1056/NEJMoa2026834

219

Kacar M, Pathak S, Savic S. Hereditary systemic autoinflammatory diseases and Schnitzler's syndrome. Rheumatology (Oxford). 2019;58(Suppl 6):vi31-vi43. doi: 10.1093/rheumatology/kez448

220

Bixio R, Rossini M, Giollo A. Efficacy of interleukin-1 blockade in Schnitzler's syndrome without detectable monoclonal gammopathy: A case-based review. Clin Rheumatol. 2021;40(7):2973-2977. doi: 10.1007/s10067-020-05501-w

221

Fujita Y, Asano T, Sakai A, Norikawa N, Yamamoto T, Matsumoto H, et al. a case of Schnitzler's syndrome without monoclonal gammopathy successfully treated with canakinumab. BMC Muscu-loskelet Disord. 2021;22(1):257. doi: 10.1186/s12891-021-04120-z

Fujita Y, Asano T, Sakai A, Norikawa N, Yamamoto T, Matsumoto H, et al. a case of Schnitzler's syndrome without monoclonal gammopathy successfully treated with canakinumab. BMC Musculoskelet Disord. 2021;22(1):257. doi: 10.1186/s12891-021-04120-z

222

Gusdorf L, Lipsker D. Neutrophilic urticarial dermatosis: An entity bridging monogenic and polygenic autoinflammatory disorders, and beyond. J Eur Acad Dermatol Venereol. 2020;34(4):685-690. doi: 10.1111/jdv.15984

223

Hartig I, Schroeder JO, Mrowietz U. Neutrophilic urticarial dermatosis (NUD) in probable adult-onset Still disease responding to anakinra. J Clin Rheumatol. 2014;20(2):96-98. doi: 10.1097/RHU.0000000000000078

224

NarvAez Garcia FJ, Pascual M, Ldpez de Recalde M, Juarez P, Morales-Ivorra I, Notario J, et al. Adult-onset Still's disease with atypical cutaneous manifestations. Medicine (Baltimore). 2017;96(11):e6318. doi: 10.1097/MD.0000000000006318

225

Verweyen EL, Pickering A, Grom AA, Schulert GS. Distinct gene expression signatures characterize strong clinical responders versus nonresponders to canakinumab in children with systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2021;73(7):1334-1340. doi: 10.1002/art.41640

The authors declare that there are no conflicts of interest present.